Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARVIND MADAN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1235104209
CMS profile
191458
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$123,374.98

220 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARVIND MADAN

NPI 1235104209 · CMS profile ID 191458

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235104209?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARVIND MADAN, NPI 1235104209, CMS profile ID 191458. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235104209?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ARVIND MADAN, NPI 1235104209, CMS profile ID 191458. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235104209?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ARVIND MADAN, NPI 1235104209, CMS profile ID 191458, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1235104209?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

220 matching records · $123,374.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 220 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 220.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kyowa Kirin, Inc. $11.6110/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025820 CMS
ANI Pharmaceuticals, Inc. $1,800.0010/04/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091136161 CMS
Novartis Pharmaceuticals Corporation $20.4110/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087070200 CMS
Ardelyx, Inc. $17.2310/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146693294 CMS
Travere Therapeutics, Inc. $6.4809/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149874083 CMS
Amgen Inc. $3,000.0009/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117316286 CMS
Travere Therapeutics, Inc. $32.6109/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149874107 CMS
Otsuka America Pharmaceutical, Inc. $29.0709/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118933336 CMS
Novartis Pharmaceuticals Corporation $73.7309/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087070188 CMS
Amgen Inc. $121.8209/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117316282 CMS
Novartis Pharmaceuticals Corporation $132.1909/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087070186 CMS
AstraZeneca Pharmaceuticals LP $2,400.0009/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104432343 CMS
Vifor Pharma, Inc. $25.1509/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124056993 CMS
AstraZeneca Pharmaceuticals LP $109.8809/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104589628 CMS
AstraZeneca Pharmaceuticals LP $125.0009/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105728575 CMS
Travere Therapeutics, Inc. $4.5909/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149874079 CMS
AstraZeneca Pharmaceuticals LP $1,200.0008/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105477713 CMS
AstraZeneca Pharmaceuticals LP $68.0108/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105499914 CMS
Aurinia Pharma U.S., Inc. $21.4808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150686665 CMS
Aurinia Pharma U.S., Inc. $0.5808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150686667 CMS
Kyowa Kirin, Inc. $12.3308/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025796 CMS
Kyowa Kirin, Inc. $2.8708/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025798 CMS
Kyowa Kirin, Inc. $38.2608/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025806 CMS
Kyowa Kirin, Inc. $7,700.0008/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025810 CMS
Kyowa Kirin, Inc. $24.1208/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025814 CMS
Kyowa Kirin, Inc. $48.0008/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025816 CMS
Novartis Pharmaceuticals Corporation $27.9808/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087070198 CMS
Otsuka America Pharmaceutical, Inc. $28.8908/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118933334 CMS
Mallinckrodt Hospital Products Inc. $11.3108/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145102083 CMS
Mallinckrodt Hospital Products Inc. $34.0008/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145102087 CMS
Mallinckrodt Hospital Products Inc. $25.4608/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145102092 CMS
Kyowa Kirin, Inc. $50.0008/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025800 CMS
Kyowa Kirin, Inc. $25.0008/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025802 CMS
Kyowa Kirin, Inc. $25.0008/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025804 CMS
Kyowa Kirin, Inc. $50.0008/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025818 CMS
Kyowa Kirin, Inc. $841.7808/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025808 CMS
Kyowa Kirin, Inc. $226.8608/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127025812 CMS
Renalytix AI, Inc. $110.8308/08/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116759410 CMS
Renalytix AI, Inc. $20.7308/07/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116759408 CMS
Amgen Inc. $25.8108/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117316264 CMS
Amgen Inc. $20.1008/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117316272 CMS
Amgen Inc. $2,700.0008/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117316274 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.0608/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086233348 CMS
GlaxoSmithKline, LLC. $120.1707/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116556393 CMS
Mallinckrodt Hospital Products Inc. $7,200.0007/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145102079 CMS
Vifor Pharma, Inc. $65.2807/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124055038 CMS
CALLIDITAS THERAPEUTICS US INC. $22.0607/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141519115 CMS
Baxter Healthcare $15.9007/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120586630 CMS
GlaxoSmithKline, LLC. $20.3607/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116650475 CMS
Janssen Biotech, Inc. $21.5007/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078468228 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $168,152.49 278
PY2020 $44,706.13 77
PY2021 $108,997.22 155
PY2022 $183,822.36 261
PY2023 $109,323.25 211
PY2024 $123,374.98 220
PY2025 $204,528.83 293

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,112,210.00 91
PY2024 Recipient $169,467.00 2
PY2024 Principal investigator $2,637,805.42 47
PY2023 Principal investigator $3,676,573.98 9
PY2022 Principal investigator $309,956.40 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

91 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $375.00 12/19/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223290012
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $526.40 12/19/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223290014
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,129.00 12/18/2025 Non-covered Recipient Entity
CTR OAKWATER
a phase I and IIa randomized,double blind,placebo controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end stage kidney disease receiving hemodialysis through a central venous catheter No dispute reported 06/30/2026 1185543506
Principal investigator 1 CSL Behring $1,200.00 12/18/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667601
Principal investigator 1 Calliditas Therapeutics US Inc. $100.00 12/15/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Nef-403 No dispute reported 06/30/2026 1235023532
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 12/12/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223289680
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 12/12/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223289684
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 12/10/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223289510
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $394.80 12/10/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223289516
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $450.00 12/05/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223289276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $263.20 12/05/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223289286
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 12/05/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223289294
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 12/05/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223289372
Principal investigator 1 Amgen Inc. $23,500.00 11/22/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246640553
Principal investigator 1 Hoffmann-La Roche Limited $100.00 11/21/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211591405
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 11/21/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223288659
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $625.00 11/12/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223288227
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 11/05/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223288009
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 11/05/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223288011
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 11/05/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223288013
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 11/05/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223288015
Principal investigator 1 Hoffmann-La Roche Limited $2,699.00 10/29/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211591393
Principal investigator 1 Hoffmann-La Roche Limited $2,600.00 10/29/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211591397
Principal investigator 1 Hoffmann-La Roche Limited $14,500.00 10/29/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211591401
Principal investigator 1 Calliditas Therapeutics US Inc. $1,000.00 10/07/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Nef-403 No dispute reported 06/30/2026 1235023500
Principal investigator 1 Amgen Inc. $72,265.69 09/24/2025 Non-covered Recipient Entity
CLINTRIAL RESEARCH OAKWATER, LLC
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246640419
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $32,739.84 09/24/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy No dispute reported 06/30/2026 1214125264
Principal investigator 1 AstraZeneca Pharmaceuticals LP $66,778.34 09/17/2025 Non-covered Recipient Entity
CENTRAL FLORIDA KIDNEY SPECIALISTS
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1185543496
Principal investigator 1 AstraZeneca Pharmaceuticals LP $55,911.41 08/29/2025 Non-covered Recipient Entity
CENTRAL FLORIDA KIDNEY SPECIALISTS
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185543500
Principal investigator 1 Calliditas Therapeutics US Inc. $1,100.00 08/12/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Nef-403 No dispute reported 06/30/2026 1235023468
Principal investigator 1 CSL Behring $16.71 08/06/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667621
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $400.00 08/05/2025 Non-covered Recipient Entity
Elixia Central Florida Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225413615
Principal investigator 1 Eli Lilly and Company $55,253.85 07/22/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187878663
Principal investigator 1 Alexion Pharmaceuticals, Inc. $42,218.55 07/18/2025 Non-covered Recipient Entity
CTR OAKWATER
a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN No dispute reported 06/30/2026 1185543502
Principal investigator 1 Alexion Pharmaceuticals, Inc. $4,049.85 07/18/2025 Non-covered Recipient Entity
ELIXIA
a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN No dispute reported 06/30/2026 1185543508
Principal investigator 1 CSL Behring $4,228.00 07/16/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667599
Principal investigator 1 Eli Lilly and Company $30,614.42 07/14/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187880990
Principal investigator 1 CSL Behring $600.00 07/07/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667595
Principal investigator 1 CSL Behring $1,350.00 07/07/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667597
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,000.00 07/07/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223282378
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 07/02/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223282184
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 07/02/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223282186
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 07/02/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223282188
Principal investigator 1 CSL Behring $2,367.00 06/30/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667593
Principal investigator 1 CSL Behring $175.00 06/23/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667589
Principal investigator 1 CSL Behring $750.00 06/23/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667591
Principal investigator 1 Aurinia Pharma U.S., Inc. $1,374.00 06/18/2025 Non-covered Recipient Entity
Elixia Central Florida, LLC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930846
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,000.00 06/13/2025 Non-covered Recipient Entity
Elixia Central Florida Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412406
Principal investigator 1 CSL Behring $2,500.00 06/11/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667587
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,439.00 06/05/2025 Non-covered Recipient Entity
Elixia Central Florida Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412180
Principal investigator 1 CSL Behring $4,734.00 05/14/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667585
Principal investigator 1 Calliditas Therapeutics US Inc. $9,600.00 05/12/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Nef-403 No dispute reported 06/30/2026 1235023432
Principal investigator 1 Aurinia Pharma U.S., Inc. $3,995.00 05/07/2025 Non-covered Recipient Entity
Elixia Central Florida, LLC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930765
Principal investigator 1 CSL Behring $600.00 05/05/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667581
Principal investigator 1 CSL Behring $2,000.00 05/05/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667583
Principal investigator 1 CSL Behring $1,861.00 04/25/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667579
Principal investigator 1 CSL Behring $10,660.00 04/16/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667577
Principal investigator 1 CSL Behring $16.71 04/11/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667619
Principal investigator 1 CSL Behring $16.71 04/10/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667615
Principal investigator 1 CSL Behring $97.31 04/10/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667617
Principal investigator 1 Calliditas Therapeutics US Inc. $10,000.00 04/10/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
Nef-403 No dispute reported 06/30/2026 1235023422
Principal investigator 1 CSL Behring $605.38 04/08/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667613
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $86.00 03/27/2025 Non-covered Recipient Entity
Elixia Central Florida Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225404640
Principal investigator 1 CSL Behring $5,452.00 03/19/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667575
Principal investigator 1 Aurinia Pharma U.S., Inc. $20,283.76 03/12/2025 Non-covered Recipient Entity
Elixia Central Florida, LLC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931056
Principal investigator 1 CSL Behring $725.86 02/21/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667611
Principal investigator 1 CSL Behring $500.00 02/19/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667571
Principal investigator 1 CSL Behring $7,120.00 02/19/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667573
Principal investigator 1 CSL Behring $15.15 02/19/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667609
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,240.00 02/06/2025 Non-covered Recipient Entity
Elixia Central Florida Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225405194
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $220.00 01/28/2025 Non-covered Recipient Entity
Elixia Central Florida Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403115
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $678.00 01/27/2025 Non-covered Recipient Entity
Elixia Central Florida Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225406516
Principal investigator 1 Eli Lilly and Company $2,560.94 01/27/2025 Non-covered Recipient Entity
ELIXIA COVID-19 LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187881698
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,366.24 01/27/2025 Non-covered Recipient Entity
ELIXIA CLINICAL RESEARCH COLLABORAT
A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy No dispute reported 06/30/2026 1190309338
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $81,107.77 01/27/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease No dispute reported 06/30/2026 1214125572
Principal investigator 1 AstraZeneca Pharmaceuticals LP $60,694.20 01/24/2025 Non-covered Recipient Entity
ELIXIA
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1185543494
Principal investigator 1 CSL Behring $2,740.00 01/24/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667553
Principal investigator 1 Eli Lilly and Company $86,826.00 01/21/2025 Non-covered Recipient Entity
ELIXIA CENTRAL FLORIDA LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187880569
Principal investigator 1 Eli Lilly and Company $77,141.00 01/21/2025 Non-covered Recipient Entity
ELIXIA CENTRAL FLORIDA LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187880571
Principal investigator 1 Novartis Pharmaceuticals Corporation $599.21 01/15/2025 Non-covered Recipient Entity
ELIXIA CLINICAL RESEARCH COLLABORAT
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids i No dispute reported 06/30/2026 1190309340
Principal investigator 1 AstraZeneca UK Limited $204,548.45 01/13/2025 Non-covered Recipient Entity
ELIXIA
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185543498
Principal investigator 1 CSL Behring $11,537.00 01/10/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667549
Principal investigator 1 CSL Behring $14,316.00 01/10/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667551
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $572,434.80 01/10/2025 Non-covered Recipient Entity
ELIXIA CENTRAL FL
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) No dispute reported 06/30/2026 1214124708
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,305.00 01/09/2025 Non-covered Recipient Entity
Elixia Central Florida Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225406514
Principal investigator 1 CSL Behring $797.36 01/08/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667605
Principal investigator 1 CSL Behring $97.31 01/08/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667607
Principal investigator 1 CSL Behring $30.26 01/07/2025 Non-covered Recipient Entity
Elixia Central Florida LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667603
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,790.80 01/03/2025 Non-covered Recipient Entity
ELIXIA
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185543504
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $226,079.77 01/02/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214123532
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $173,061.95 01/01/2025 Non-covered Recipient Entity
CTR OAKWATER LLC
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214125574